Literature DB >> 16516910

Sustained augmentation of cardiac alpha1A-adrenergic drive results in pathological remodeling with contractile dysfunction, progressive fibrosis and reactivation of matricellular protein genes.

H Chaulet1, F Lin, J Guo, W A Owens, J Michalicek, S H Kesteven, Z Guan, O W Prall, B M Mearns, M P Feneley, S F Steinberg, R M Graham.   

Abstract

We previously reported that transgenic (TG) mice with cardiac-restricted alpha(1A)-adrenergic receptor (alpha(1A)-AR)-overexpression showed enhanced contractility, but no hypertrophy. Since chronic inotropic enhancement may be deleterious, we investigated if long-term, cardiac function and longevity are compromised. alpha(1A)-TG mice, but not their non-TG littermates (NTLs), showed progressive loss of left ventricular (LV) hypercontractility (dP/dt(max): 14,567+/-603 to 11,610+/-915 mmHg/s, P<0.05, A1A1 line: 170-fold overexpression; and 13,625+/-826 to 8322+/-682 mmHg/s, respectively, P<0.05, A1A4 line: 112-fold overexpression, at 2 and 6 months, respectively). Both TG lines developed LV fibrosis, but not LV dilatation or hypertrophy, despite activation of hypertrophic signaling pathways. Microarray and real time RT-PCR analyses revealed activation of matricellular protein genes, including those for thrombospondin 1, connective tissue growth factor and tenascin C, but not transforming growth factor beta1. Life-span was markedly shortened (mean age at death: 155 days, A1A1 line; 224 days, A1A4 line compared with NTLs: >300 days). Telemetric electrocardiography revealed that death in the alpha(1A)-AR TG mice was due to cardiac standstill preceded by a progressive diminution in QRS amplitude, but not by arrhythmias. The QRS changes and sudden death could be mimicked by alpha(1)-AR activation, and reversed preterminally by alpha(1)-AR blockade, suggesting a relationship to stress- or activity-associated catecholamine release. Thus, long-term augmentation of cardiac alpha(1A)-adrenergic drive leads to premature death and progressive LV fibrosis with reactivation of matricellular protein genes. To our knowledge this is the first evidence in vivo for a role of the alpha(1A)-AR in ventricular fibrosis and in pathological cardiac remodeling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16516910     DOI: 10.1016/j.yjmcc.2006.01.015

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  17 in total

Review 1.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

Review 2.  Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure.

Authors:  Brian C Jensen; Timothy D O'Connell; Paul C Simpson
Journal:  J Mol Cell Cardiol       Date:  2010-11-28       Impact factor: 5.000

Review 3.  Cardiac and neuroprotection regulated by α(1)-adrenergic receptor subtypes.

Authors:  Dianne M Perez; Van A Doze
Journal:  J Recept Signal Transduct Res       Date:  2011-02-21       Impact factor: 2.092

4.  Alpha(1D)-adrenergic receptor insensitivity is associated with alterations in its expression and distribution in cultured vascular myocytes.

Authors:  Lin-lin Fan; Shuang Ren; Hong Zhou; Ying Wang; Ping-xiang Xu; Jun-qi He; Da-li Luo
Journal:  Acta Pharmacol Sin       Date:  2009-12       Impact factor: 6.150

Review 5.  Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance.

Authors:  Timothy D O'Connell; Brian C Jensen; Anthony J Baker; Paul C Simpson
Journal:  Pharmacol Rev       Date:  2013-12-24       Impact factor: 25.468

Review 6.  Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47.

Authors:  David R Soto-Pantoja; Erica V Stein; Natasha M Rogers; Maryam Sharifi-Sanjani; Jeffrey S Isenberg; David D Roberts
Journal:  Expert Opin Ther Targets       Date:  2012-10-27       Impact factor: 6.902

Review 7.  Alpha-1-adrenergic receptors in heart failure: the adaptive arm of the cardiac response to chronic catecholamine stimulation.

Authors:  Brian C Jensen; Timothy D OʼConnell; Paul C Simpson
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

8.  {alpha}1-Adrenergic receptor subtypes in nonfailing and failing human myocardium.

Authors:  Brian C Jensen; Philip M Swigart; Teresa De Marco; Charles Hoopes; Paul C Simpson
Journal:  Circ Heart Fail       Date:  2009-08-06       Impact factor: 8.790

Review 9.  Adrenergic signaling in heart failure: a balance of toxic and protective effects.

Authors:  Anthony J Baker
Journal:  Pflugers Arch       Date:  2014-03-14       Impact factor: 3.657

10.  Thrombospondins in the heart: potential functions in cardiac remodeling.

Authors:  Mark W M Schellings; Geert C van Almen; E Helene Sage; Stephane Heymans
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.